Antibody response against three Plasmodium falciparum merozoite antigens in Mamuju District, West Sulawesi Province, Indonesia by Nanggung, Nurhayana Sennang Andi
Sennang et al. Malaria Journal 2014, 13:381
http://www.malariajournal.com/content/13/1/381RESEARCH Open AccessAntibody response against three Plasmodium
falciparum merozoite antigens in Mamuju District,
West Sulawesi Province, Indonesia
Nurhayana Sennang1, Stephen Rogerson2, Sitti Wahyuni3, Irawan Yusuf4 and Din Syafruddin3,5*Abstract
Background: Malaria endemicity in the archipelago of Indonesia varies substantially across regions. Following the
government’s plan for a malaria elimination programme in Indonesia, baseline malaria surveys were conducted in
Mamuju District, West Sulawesi Province, Indonesia to re-assess the malaria situation prior to the establishment of
an evidence-based malaria elimination programme in the area. The present study aims to determine the antibody
response to three merozoite antigens among the inhabitants of the district.
Methods: Antibodies were measured following elution from filter-paper blood spots collected during cross-sectional
surveys in the dry and wet season in 2010. Enzyme-linked immunosorbent assays using three merozoite antigens, MSP2,
EBA175 and PfRh2a were conducted. A positivity threshold was determined by samples from unexposed individuals and
the difference in antibody level against each antigen and correlation of antibody level in different age groups and seasons
were statistically analysed.
Results: A total of 497 subjects, 248 in dry and 249 in wet season, aged between 0.6 and 78 years were included. The
prevalence of positive antibody responses to MSP2, EBA175 and PfRh2a antigens in dry season were 27.82, 27.42 and
25.81%, respectively. In wet season, the antibody prevalences were 64.26, 64.66 and 61.45%. The antibody levels to the
three antigens were all higher in older age groups and also significantly higher in the wet season. The antibody levels
also correlated positively with the Plasmodium falciparum infection status of the subjects.
Conclusion: MSP2, EBA175 and PfRh2a induce antibody responses among the subjects in Mamuju District, and the
prevalence is significantly higher in wet season. The level of antibody also correlates significantly with age and malaria
positivity. The overall results indicate the antigens might be used as a target for vaccines against P. falciparum infection
and as markers for malaria exposure.
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Malaria remains one of the major public health problems
in many tropical countries around the world, including
Indonesia. In 2013, of the 97 countries with ongoing
malaria transmission, 11 were in pre-elimination phase
and seven in elimination phase [1]. In Indonesia, malaria
endemicity varies substantially across different regions, in
which Java and Bali islands are very low endemicity,
whereas outer islands are meso- to highly endemic. The* Correspondence: din@eijkman.go.id
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unless otherwise stated.government of Indonesia developed a plan for malaria
elimination in 2009 and each region has set different time-
lines for elimination phases [2]. In eastern Indonesia,
malaria control efforts continue to rely heavily on che-
motherapy and vector control through provision of
insecticide-treated nets. As in many other countries in the
Asia-Pacific region, Plasmodium falciparum and Plasmo-
dium vivax are the major causative species of malaria in
Indonesia. Plasmodium malariae and Plasmodium ovale
occurred infrequently, mainly in eastern Indonesia.
Malaria symptoms in humans are exclusively caused by
the erythrocytic stage of the parasite and therefore vaccine
development is mainly focused to prevent the invasional Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sennang et al. Malaria Journal 2014, 13:381 Page 2 of 7
http://www.malariajournal.com/content/13/1/381and development of the parasite in this stage. Children
and pregnant women are the most vulnerable groups in
areas of stable malaria, and after repeated exposures indi-
viduals develop immunity to the blood stage parasite,
thereby reducing the risk of clinical symptoms and life-
threatening complications. To date, various merozoite
proteins have been implicated in the erythrocyte invasion,
and some of these have been identified as targets for vac-
cine development and markers for epidemiologic studies
[3]. Antibodies to merozoite antigens are considered im-
portant targets of protective antibodies and are thought to
function in vivo by inhibiting merozoite invasion of eryth-
rocytes, opsonizing merozoites for phagocytosis, and indu-
cing antibody-dependent cellular inhibition.
Invasion of the erythrocytes by the malarial parasite in-
volves several families of merozoite proteins during the
initial step of attachment, reorientation, penetration, and
formation of the parasitophorous vacuole. This includes
merozoite surface protein family (MSP), erythrocyte
binding-like protein (EBP) and the reticulocyte binding-
like or reticulocyte homologue proteins (RBL or PfRh).
Many of the proteins are being evaluated as targets for
anti-malarial vaccine candidates [4,5]. Merozoite surface
protein 2 (MSP2) is one of the MSP family members that
has been extensively studied and the antibody response to
this protein has been associated with protection against
malaria. Erythrocyte binding antigen-175 (EBA-175) is a
175-kilodalton EBP of P. falciparum parasites that medi-
ates erythrocyte invasion. EBA-175 is found in the micro-
nemes of merozoites, which secrete EBA-175 to bind
erythrocytes that are ready to be invaded [6,7]. Analysis of
sera from malaria-endemic areas to determine the pres-
ence of specific antibody EBA-175 revealed some relation-
ships with protection in children with higher antibody
titres [8].
Reticulocyte binding-like protein (protein RBL) of Plas-
modium is one of the classes of type 1 transmembrane lig-
and parasites localized in the rhoptry. A recent study
indicated that antibodies that target the binding domain of
PfRh2a inhibited the invasion of the erythrocyte by the
merozoites [9].
The present study aims to measure antibody responses
against merozoite proteins MSP2, EBA-175 and PfRh2a in
Mamuju District, West Sulawesi, a malaria-endemic re-
gion in eastern Indonesia and to evaluate the asso-
ciation between antibody levels, malaria infection, age,
and season.
Methods
Study site
The study was a part of research activities to establish
an evidence-based malaria control programme in the
Mamuju District, West Sulawesi Province, Indonesia
through assessment of the baseline malaria prevalence inthe area. Mamuju District is located within 2°40’- 3°39’
south latitude and 118°46’- 119°25’ east longitude and
divided into 15 subdistricts. The District occupies an
area of 8,014 sq km along the midwest coastal region of
the island of Sulawesi with a total population of 336,973
(Figure 1). The population mainly consists of Mandarese
and Buginese ethnic groups with some resettlers from
the islands of Java, Bali and Lombok. This area is known
to be endemic for malaria and lymphatic filariasis [10].
Multistage, random sampling cross-sectional surveys
was conducted in Mamuju District, West Sulawesi
Province, Indonesia during the dry and wet seasons of
2010. Subjects were asked to provide written informed
consent for finger-prick blood smears and blood blots
for DNA and immunologic analysis. This study received
ethics approval for the use of human subjects from the
Ethics Committee, Faculty of Medicine, Hasanuddin
University.
Sample selection
A total of 4,406 and 4,706 samples in the forms of filter
paper blood spots were collected during the baseline
malaria surveys performed during the dry (August) and
rainy season (December), respectively, in 2010. The
samples were further selected for immunological assays
using all confirmed falciparum malaria cases by micros-
copy and polymerase chain reaction amplification (PCR).
In addition, 5% of the total negative samples, selected ran-
domly and representing proportionally all the villages’
population, were also included.
Deoxyribonucleic Acid (DNA) extraction and polymerase
chain reaction amplification
The parasite DNA was extracted from the filter paper
using Chelex-100 ion exchanger method as described
previously [11]. The DNA extract was used as template
for the nested PCR using oligos that target the parasite
MSP2 genes [12].
Immunologic assays
Elution of antibodies from blood spots
Elution of the antibodies from the filter paper was essen-
tially done as that described previously with slight modi-
fication [13,14]. Plastic bags containing blood spots were
allowed to return to ambient temperature before open-
ing. Discs of 4.5 mm in diameter were cut from the filter
paper using a paper puncher (Kangaro punch, Kanin
India Ltd, Delhi, India). The individual disc was trans-
ferred into a 1.5 ml Eppendorf microtube containing
0.05% Tween 20 and 0.5% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS). Following
incubation for two hours at room temperature (RT) on
a shaker and vortexing for a few seconds, the liquid
Figure 1 Mamuju District in West Sulawesi indicated by the box and location within the Indonesian archipelago (inset). Not to scale.
Table 1 Characteristics of study subjects
Variable n %
Sex
Male 207 41.65
Female 290 58.35
Age category
<= 5 years 55 11.07
> 5 years 442 88.93
Sampling time
Dry season 248 49.9
Rainy season 249 50.1
P. falciparum PCR
Positive 59 11.87
Negative 438 88.13
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and kept at −20°C until use.
Enzyme-linked immunosorbent assays
Recombinant MSP2, EBA175 and Rh2A9 proteins were
all gifts from Prof J Beeson of the Burnet Institute,
Australia. Total immunoglobulin (IgG) responses to
MSP2 (3D7 allele), EBA175 and Rh2a were measured
using enzyme-linked immunosorbent assay (ELISA) as
described previously [9,15]. Briefly, the sera was ex-
tracted from the filter paper using a paper puncher with
diameter of 6 mm and transfered to a 1.5 ml Eppendorf
micotube containing 500 ml PBS, 0.05% Tween 20 and
0.5% BSA. Following incubation on a rotatory shaker at
RT for two hours, the supernatant was transferred to a
new, sterile 1.5 ml Eppendorf microtube and used for
ELISA. Antibody levels were expressed in arbitrary units
(AUs), calculated by dividing the optical density (OD) of
the sample by the mean OD plus three standard deviations
(SD) of samples from control samples (samples from indi-
viduals never exposed to malaria). Positive control samples
Table 2 IgG level to MSP2, EBA-175 and PfRh2a Plasmodium falciparum based in the dry and wet season
Variables Dry season (n = 248) Wet season (n = 249) p*
Antibody prevalence (%) Median (IQR) Antibody prevalence (%) Median (IQR)
IgG MSP2 27.82% 4.47 (2.76-9.24) 64.26% 5.16 (3.52-9.78) <0.001
IgG EBA-175 27.42% 9.71 (6.58-16.54) 64.66% 11.49 (8.82-16.78) <0.001
IgG PfRh2a 25.81% 3.05 (2.51-6.19) 61.45% 4.47 (3.46-6.03) <0.001
(*) was determined by using Mann–Whitney test.
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were placed on each plate and values were similar on all
test days.
Statistical analysis
Statistical analysis was performed using software of
IBM SPSS Statistics 22. To test for differences in anti-
body levels for the three antibodies, MSP2, EBA175,
and PfRh2a, based on sampling time, malaria positivity
and age, Mann–Whitney test was used. The median dif-
ferences of the three antibodies based on age group
were determined using Kruskal Wallis test. Spearman
correlation test was used to determine the association
between the level of MSP2, EBA175 and PfRh2a anti-
bodies with age.
Results
Demographic characteristics of the subjects
Demographic characteristics of the subjects are shown
in Table 1. Of the total 497 subjects selected, 207 were
men and 290 were women. Fifty-five subjects were < five
years old (11.07%). Samples collected in the dry season
were 248 (49.90%). There were 59 samples that were
positive for P. falciparum based on the results of PCR
(Table 1).
Enzyme-linked immunosorbent assay (ELISA)
Merozoite surface protein-2 (MSP2) antibodies
The prevalence of positive antibody response to MSP2
antigens among the subjects in the dry and wet seasonTable 3 IgG prevalence to MSP2, EBA-175 and PfRh2a Plasmo
Age groups IgG MSP2 (unit) IgG
Antibody
prevalence (%)
Median (IQR) An
pre
0-12 years 31.82% 1.07 32.
(n = 110) (0.40-2.76)
13-40 years 37.30% 1.41 38.
(n = 126) (0.74-3.78)
>40 years 42.86% 1.74 40.
(n = 49) (0.40-4.29)
p (ROH) (Kruskall Wallis test) 0.15
p (Spearman Correlation) 0.07was 27.82% (median 4.47, IQR 2.76-9.24) and 64.26%
(median 5.16, IQR 3.52-9.78), respectively (Table 2). The
difference in the antibody level against MSP2 between the
dry and wet season was statistically significant (p <0.001).
Erythrocyte binding antigen (EBA175) antibodies
Antibody response to EBA-175 antigen is shown in
Table 2. The prevalence of positive antibody response to
EBA-175 antigen among the subjects in the dry and wet
season was 27.42% (median 9.71, IQR6.58-16.54) and
64.66% (median 11.49, IQR 8.82-16.78), respectively.
The difference in the antibody response between the dry
and wet season was statistically significant (p < 0.001).
Plasmodium falciparum rhoptry 2a (PfRh2a) antibodies
Antibody response to PfRh2a antigen in the two col-
lected seasons is shown in Table 2. The prevalence of
positive antibody response to PfRh2a antigen among the
subjects in the dry and wet season was 25.81% (median
level 3.05, IQR 2.51-6.19) and 61.45% (median 4.47, IQR
3.46-6.03), respectively. The difference in the antibody
response between the dry and wet season was statisti-
cally significant (p < 0.001).
Antibody prevalence and the age group
The prevalence of antibody response to MSP2, EBA-175
and PfRh2a in different age groups is shown in Table 3.
The antibody prevalence to MSP2 and EBA-175 in-
creased in the older age groups, whereas for PfRh2a, the
antibody prevalence is relatively constant by age.dium falciparum based on age group
EBA-175 (unit) IgG PfRh2a (unit)
tibody
valence (%)
Median (IQR) Antibody
prevalence (%)
Median (IQR)
73% 3.61 36.36% 1.49
(1.97-7.47) (0.78-2.78)
10% 3.84 33.33% 1.49
(2.44-9.27) (1.01-3.05)
82% 3.38 36.73% 1.49
(2.21-8.59) (0.78-2.78)
0.31 0.66
0.31 0.97
Table 4 Level of IgG MSP2, EBA-175 and PfRh2a (units) in age < = 12 years and age >12 years groups (n = 285)
Variables Age < =12 years (n = 110) Age >12 years (n = 175) P*
Median IQR Median IQR
IgG MSP2 (unit) 1.07 (0.40-2.76) 1.41 (0.74-4.12) 0.05
IgG EBA-175 (unit) 3.61 (1.98-7.48) 3.84 (2.45-8.82) 0.16
IgG PfRh2a (unit) 1.50 (0.78-2.77) 1.50 (0.78-2.89) 0.68
(*) was determined by using Mann–Whitney test.
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Based on the age group, the median levels of IgG re-
sponse to MSP2 and EBA-175 were slightly higher in
subjects ≥12 years old versus those <12 years old
(Table 4). The difference in the level of antibodies, how-
ever, was only statistically significant for the MSP2 (p =
0.05). The median level of antibody to PfRh2a in all age
groups was relatively constant.
Antibody level and malaria positivity
Of the 497 subjects included in this study, 59 were con-
firmed to be falciparum infected, based on the PCR de-
tection method (Table 5). The median antibody level to
MSP2, EBA-175 and PfRh2a antigens was higher in the
falciparum-infected subjects versus uninfected subjects.
The difference in antibody level to MSP2, EBA-175 and
PfRh2a is not statistically significant.
Discussion
The antibody responses to the P. falciparum merozoite
proteins MSP2, EBA-175 and PfRh2a were detected in
subjects living in the malaria-endemic areas of Mamuju
District, West Sulawesi Province, Indonesia and the re-
sponses are significantly higher in the wet season. The
findings indicate that the three antigens might poten-
tially be used as markers for exposure to malaria. Anti-
body responses to various merozoite proteins have been
well documented in different population studies, but
only few of the antigens was found to confer protection
against clinical malaria [16]. In Indonesia, there are very
limited data regarding the antibody profiles of merozoite
proteins and their association with protection to malaria
[17-19]. A previous study showed that antibody response
to MSP1 and apical membrane antigen 1(AMA-1) is
higher in high transmission season in comparison to the
low transmission season. The findings are in accordanceTable 5 Antibody level to MSP2, EBA-175, PfRh2a and malari
Variables P. falciparum-positive (n = 59)
Median IQR
IgG MSP2 (unit) 2.42 (0.74-10.15)
IgG EBA-175 (unit) 6.58 (1.98-14.57)
IgG PfRh2a (unit) 2.51 (0.78-4.77)
(*) was determined by using Mann–Whitney test.with the results of this study where the antibody response
to the three merozoite antigens examined was found to be
higher in the wet season when the transmission was high
[10,20]. In a cohort study in Gambian children, increased
levels of serum IgG antibodies against P. falciparum mero-
zoite antigens were observed in many children during the
rainy season. The levels of antibody to AMA-1, EBA-175,
MSP119 and MSP2 increased at the end of the rainy sea-
son in children who had experienced clinical symptoms of
malaria [21].
Antibody responses to MSP2 and EBA-175 have also
been associated with protection from clinical malaria in
adult subjects [22]. In this study, although the antibody
levels in older age groups were higher for both MSP2
and EBA-175, the differences were only statistically sig-
nificant for MSP2 due to the high variation within the
age group. The levels of antibody response to MSP2,
EBA-175 and PfRh2a were also found to be slightly higher
in P. falciparum-positive subjects although this difference
was not statistically significant. Further study involving
larger sample size and specific IgG subclasses may provide
a more conclusive result in this regard.
Antibody response to the PfRh2a antigen was also ob-
served, and the levels tend to constant with age. PfRh2a
and PfRh2b proteins are identical for 2700 N-terminal
amino acids and differed only in a C-terminal 500 amino
acid region, which includes a unique ectodomain, trans-
membrane domain and cytoplasmic domain [5]. Anti-
bodies raised against the binding domains of the PfRh2a
and PfRh2b at the N terminus blocked the merozoite in-
vasion [9]. It is therefore possible that the antibody re-
sponse to PfRh2a detected in this study, may have
simultaneously been targeted to PfRh2b antigen.
A study involving 206 children in Papua New Guinea
demonstrated that the IgG1 and IgG3 levels were
predominantly higher in children who had parasitaemiaa positivity
P. falciparum -negative (n = 438) P*
Median IQR
1.74 (0.74-4.47) 0.11
4.30 (2.45-10.16) 0.42
1.50 (0.78-3.89) 0.31
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Interestingly, they found that antibody responses to
PfRh2a were associated with age and active infection. High
levels of IgG to PfRh2 were strongly associated with pro-
tection from malaria symptoms and parasitaemia [15].
Conclusion
Antibody responses against three merozoites proteins were
observed in the population of Mamuju District, West
Sulawesi Province, Indonesia. The increase of the antibody
response during the wet season indicates the high malaria
transmission during the period. Therefore, MSP2, EBA-175
and PfRh2a are potentially useful as markers for malaria ex-
posure. Among the three merozoite proteins examined,
only the MSP2 showed protective efficacy as indicated in
the higher level in the older age group and malaria-positive
subjects. This study has a limitation as the assays were per-
formed using archived filter-paper blood spots collected
during the baseline malaria survey. Analysis of the total
samples collected during the survey, although it would be
laborious and require more logistics, may provide more
conclusive results.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NS, WS and DS performed samples collection, molecular assays, data analysis,
and manuscript writing. NS, SR and DS designed the study, data analysis and
manuscript writing. NS and DS were responsible for management and fund
raising for this study. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Prof Idrus Paturusi, then Rector of Hasanuddin University,
and Prof Sangkot Marzuki, Director of the Eijkman Institute for Molecular
Biology for his kindness in permitting us to conduct the laboratory study at
the Eijkman Institute, Jakarta. We are greatly indebted to study participants
and the staff of the Mamuju District Health Staff for their technical assistance
and support during the baseline surveys, and all staff of the Malaria
Laboratory, Eijkman Institute, Jakarta for their assistance and support. This
manuscript is part of NS’s dissertation for her doctoral course in the Faculty
of Medicine, Hasanuddin University. NS wrote the first draft manuscript
under the Manuscript Writing Workshop organized by INA-RESPOND.
This study received financial support through the Competence-based
Competitive Research grant, provided by the Ministry of National Education,
Republic of Indonesia.
Author details
1Department of Clinical Pathology, Faculty of Medicine, Hasanuddin
University, Makassar 90245, South Sulawesi, Indonesia. 2Department of
Medicine, Post Office Royal Melbourne Hospital, University of Melbourne,
Melbourne, Victoria, Australia. 3Department of Parasitology, Faculty of
Medicine, Hasanuddin University, Makassar 90245, South Sulawesi, Indonesia.
4Department of Physiology, all at Faculty of Medicine, Hasanuddin University,
Makassar 90245, South Sulawesi, Indonesia. 5Eijkman Institute for Molecular
Biology, Jakarta 10430, Indonesia.
Received: 24 July 2014 Accepted: 18 September 2014
Published: 25 September 2014
References
1. WHO: World Malaria Report 2013. Geneva: World Health Organization; 2013.
2. Asih PBS, Rozi IE, Herdiana, Pratama NR, Hidayati APN, Marantina SS, Kosasih S,
Chand K, Wangsamuda S, Rusdjy FA, Sumiwi ME, Imran A, Yuniarti T, Sianturi T,Nur J, Asnita B, Barussanah C, Yani M, Ainun C, Jamil K, Mariam C, Sengkerij SP,
Laihad FJ, Hawley W, Syafruddin D: The baseline distribution of malaria in the
initial phase of elimination in Sabang Municipality, Aceh Province,
Indonesia. Malar J 2012, 11:291.
3. Richards JS, Beeson JG: The future for blood stage vaccines against
malaria. Immunol Cell Biol 2009, 87:377–390.
4. Cowman AF, Crabb BS: Invasion of red blood cells by malaria parasites.
Cell 2006, 124:755–766.
5. Dvorin JD, Bei AK, Coleman BI, Duraisingh MT: Functional diversification
between two related Plasmodium falciparum merozoite invasion ligands
is determined by changes in the cytoplasmic domain. Mol Microbiol 2010,
75:990–1006.
6. Camus D, Hadley TJ: A Plasmodium falciparum antigen that binds to host
erythrocytes and merozoites. Science 1985, 230:553–556.
7. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH: Receptor and ligand
domains for invasion of erythrocytes by Plasmodium falciparum. Science
1994, 264:1941–1944.
8. Fowkes FJ, Richards JS, Simpson JA, Beeson JG: The relationship between
anti-merozoite antibodies and incidence of Plasmodium falciparum
malaria: a systematic review and meta-analysis. PLoS Med 2010,
7:e1000218.
9. Triglia T, Chen L, Lopaticki S, Dekiwadia C, Riglar DT, Hodder AN, Ralph SA,
Baum J, Cowman AF: Plasmodium falciparum merozoite invasion is
inhibited by antibodies that target the PfRh2a and b binding domains.
PLoS Pathog 2011, 7:e1002075.
10. Nurdin A, Syafruddin D, Wahid I, Noor NN, Sunahara T, Mogi M: Malaria and
Anopheles spp. in the villages of Salubarana and Kadaila, Mamuju
District, South Sulawesi Province, Indonesia. Med J Indonesia 2003,
12:252–258.
11. Wooden J, Kyes S, Sibley CH: PCR and strain identification in Plasmodium
falciparum. Parasitol Today 1993, 9:303–305.
12. Snounou G, Farnert A: Genotyping of Plasmodium falciparum parasites by
PCR: msp1, msp2 and glurp. In Methods in Malaria Research. Edited by Moll
K, Kaneko A, Scherf A, Wahlgren M. Manassas, VA, USA: MR4/ATCC;
2013:311–314. http://www.mr4.org/Portals/3/Methods_In_Malaria_Research-
6th_edition.pdf.
13. Kaneko A: Field blood sampling: serum extraction from filter-paper sam-
ples. In Methods in Malaria Research. Edited by Moll K, Kaneko A, Scherf A,
Wahlgren M. Manassas, VA, USA: MR4/ATCC; 2013:405. http://www.mr4.org/
Portals/3/Methods_In_Malaria_Research-6th_edition.pdf.
14. Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, Griffin J, Cox J,
Abeku T, Bousema T, Ghani AC, Drakeley C, Riley E: Dried blood spots as a
source of anti- malarial antibodies for epidemiological studies. Malar J
2008, 7:195.
15. Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, Chokejindachai W,
Michon P, Tavul L, Siba PM, Cowman AF, Mueller I, Beeson JG: Evidence
that the erythrocyte invasion ligand PfRh2 is a target of protective
immunity against Plasmodium falciparum malaria. J Immunol 2010,
185:6157–6167.
16. Richard JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross
N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba
PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman
AF, Tsuboi T, Beeson JG: Identification and prioritization of merozoite
antigens as targets of protective human immunity to Plasmodium
falciparum malaria for vaccine and biomarker development. J Immunol
2013, 191:795–809.
17. Toure FS, Deloron P, Migot-Nabias F: Analysis of human antibodies to
erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum.
Clin Med Res 2006, 4:1–6.
18. Jensen JB, Hoffman SL, Boland MT, Akood MA, Laughlin LW, Kurniawan L,
Marwoto HA: Comparison of immunity to malaria in Sudan and
Indonesia: Crisis-form versus merozoite-invasion inhibition. Proc Natl
Acad Sci U S A 1984, 81:922–925.
19. Woodberry T, Minigo G, Piera KA, Hanley JC, de Silva HD, Salwati E,
Kenangalem E, Tjitra E, Coppel RL, Price RN, Anstey NM, Plebanski M:
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite
surface protein 5 in Indonesia: species-specific and cross-reactive
responses. J Infect Dis 2008, 198:134–142.
20. Supargiyono S, Bretscher MT, Wijayanti MA, Sutanto I, Nugraheni D,
Rozqie R, Kosasih AY, Sulistyawati, Hawley WA, Lobo NF, Cook J, Drakeley CJ:
Seasonal changes in the antibody responses against Plasmodium
Sennang et al. Malaria Journal 2014, 13:381 Page 7 of 7
http://www.malariajournal.com/content/13/1/381falciparum merozoite surface antigens in areas of differing malaria
endemicity in Indonesia. Malar J 2013, 12:444.
21. Akpogheneta OJ, Dunyo S, Conway DJ: Boosting antibody responses to
Plasmodium falciparum merozoite antigens in children with highly
seasonal exposure to infection. Parasite Immunol 2010, 32:296–304.
22. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B,
Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE,
Mackinnon MJ, Conway DJ, Marsh K: Breadth and magnitude of antibody
responses to multiple Plasmodium falciparum merozoite antigens are
associated with protection from clinical malaria. Infect Immun 2008,
76:2240–2248.
doi:10.1186/1475-2875-13-381
Cite this article as: Sennang et al.: Antibody response against three
Plasmodium falciparum merozoite antigens in Mamuju District, West
Sulawesi Province, Indonesia. Malaria Journal 2014 13:381.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
